-
German factory orders rise at fastest rate in 2 years in December
-
Nigeria president deploys army after new massacre
-
Ukraine, Russia, US start second day of war talks
-
Nepal's youth lead the charge in the upcoming election
-
Sony hikes forecasts even as PlayStation falters
-
Rijksmuseum puts the spotlight on Roman poet's epic
-
Trump fuels EU push to cut cord with US tech
-
Fearless talent: Five young players to watch at the T20 World Cup
-
India favourites as T20 World Cup to begin after chaotic build-up
-
Voter swings raise midterm alarm bells for Trump's Republicans
-
Australia dodges call for arrest of visiting Israel president
-
Countries using internet blackouts to boost censorship: Proton
-
Top US news anchor pleads with kidnappers for mom's life
-
Thailand's pilot PM on course to keep top job
-
The coming end of ISS, symbol of an era of global cooperation
-
New crew set to launch for ISS after medical evacuation
-
Family affair: Thailand waning dynasty still election kingmaker
-
Japan's first woman PM tipped for thumping election win
-
Stocks in retreat as traders reconsider tech investment
-
LA officials call for Olympic chief to resign over Epstein file emails
-
Ukraine, Russia, US to start second day of war talks
-
Fiji football legend returns home to captain first pro club
-
Trump attacks US electoral system with call to 'nationalize' voting
-
Barry Manilow cancels Las Vegas shows but 'doing great' post-surgery
-
US households become increasingly strained in diverging economy
-
Four dead men: the cold case that engulfed a Colombian cycling star
-
Super Bowl stars stake claims for Olympic flag football
-
On a roll, Brazilian cinema seizes its moment
-
Rising euro, falling inflation in focus at ECB meeting
-
AI to track icebergs adrift at sea in boon for science
-
Indigenous Brazilians protest Amazon river dredging for grain exports
-
Google's annual revenue tops $400 bn for first time, AI investments rise
-
Last US-Russia nuclear treaty ends in 'grave moment' for world
-
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
-
Man City brush aside Newcastle to reach League Cup final
-
Guardiola wants permission for Guehi to play in League Cup final
-
Boxer Khelif reveals 'hormone treatments' before Paris Olympics
-
'Bad Boy,' 'Little Pablo' and Mordisco: the men on a US-Colombia hitlist
-
BHP damages trial over Brazil mine disaster to open in 2027
-
Dallas deals Davis to Wizards in blockbuster NBA trade: report
-
Iran-US talks back on, as Trump warns supreme leader
-
Lens cruise into French Cup quarters, Endrick sends Lyon through
-
No.1 Scheffler excited for Koepka return from LIV Golf
-
Curling quietly kicks off sports programme at 2026 Winter Olympics
-
Undav pokes Stuttgart past Kiel into German Cup semis
-
Germany goalkeeper Ter Stegen to undergo surgery
-
Bezos-led Washington Post announces 'painful' job cuts
-
Iran says US talks are on, as Trump warns supreme leader
-
Gaza health officials say strikes kill 24 after Israel says officer wounded
-
Empress's crown dropped in Louvre heist to be fully restored: museum
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
W.Lapointe--BTB